TABLE 1.
Strains and plasmids used in this study
| Strain or plasmid | Descriptiona | Reference or source |
|---|---|---|
| Strains | ||
| E. tarda | ||
| PPD130/91 | Wild type; Kms Colr Amps | 28 |
| ΔeseB | PPD130/91 with in-frame deletion of eseB | 15 |
| ΔflhB | PPD130/91 with in-frame deletion of flhB | 7 |
| ΔeseB/pJN105-eseB | ΔeseB with pJN105-eseB | This study |
| E. coli | ||
| DH5α | α complementation | TaKaRa |
| BL21(DE3) | E. coli B F− ompT hsdS(rB− mB−) dcm+ Tetr gal (DE3) endA Hte | Novagen |
| Plasmids | ||
| pMD18-T | Cloning vector, Ampr | TaKaRa |
| pJN105 | Arabinose-inducible gene expression vector; araC-PBAD; Gmr | 29 |
| pJN105-eseB | pJN105 with wild-type eseB | This study |
| pET-28b | Cloning vector; Kmr | Novagen |
| pET-28b-eseB | pET-28b with eseB | This study |
| pFPV25.1 | Derivative of pBR322 with gfpmut3A under the control of the constitutive promoter | 30 |
a
Km, kanamycin; Col, colistin; Amp, ampicillin; Gm, gentamicin. Superscript r and s indicate resistance and sensitivity, respectively.